News

Tagworks will present how its Click-to-Release platform affords in vivo control over drug activity to address the limited therapeutic window and application scope of several targeted cancer therapies, applied to ADCs (i.e. TGW101, Tagworks’ lead clinical program) as well as targeted radiotherapies. The Antibody Engineering & Therapeutics Europe Conference will …

We’re proud to share that Nature Biotechnology has published a new article featuring an interview with our CEO, Marc Robillard. The article includes a dedicated section on Tagworks, beginning on page three and continuing into page four. We invite you to read the full article via this link.

On June 19th, 2025, Marc Robillard will give a presentation about Tagworks’ Click-to-Release platform for ADCs and targeted radiotherapies at the Johnson & Johnson R&D Symposium on Antibody Conjugates in Beerse, Belgium. At this symposium exciting advancements in discovery and development of antibody-drug conjugates and targeted radiotherapies are explored by …

Tagworks initiates Phase 1 trial for TGW101, a first-in-class Click-to-Release ADC targeting TAG-72, and appoints Dr. Keith Orford as Chief Medical Officer.

Tagworks to present preclinical data demonstrating potential of its Click-to-Release platform to enable safe, tolerable, and potent delivery of therapeutic candidates for solid tumors

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025

Marc Robillard will present the progress of Tagworks click-cleavable radiotherapeutics program at the 6th Targeted Radiopharmaceuticals Summit in Amsterdam on December 5, 2024.

We are excited to announce a recent addition to our rapidly expanding team: Krisztina Nemenyi has joined as our Vice President Regulatory Affairs.

Madeira, September 4-6, 2024; www.antibodyseries.com

Boston, September 9-10, 2024; www.adc-partnering.com